Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel Free HOWL Stock Alerts

Werewolf Therapeutics (HOWL) Competitors

Werewolf Therapeutics logo
$0.94 -0.05 (-5.46%)
As of 09/3/2026 04:00 PM Eastern
Compare

HOWL vs. NGEN, MDWD, TNYA, OKUR, and CNTB

Should you buy Werewolf Therapeutics stock or one of its competitors? Werewolf Therapeutics's main competitors and comparable companies include NervGen Pharma (NGEN), MediWound (MDWD), Tenaya Therapeutics (TNYA), OnKure Therapeutics (OKUR), and Connect Biopharma (CNTB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Werewolf Therapeutics compare to NervGen Pharma?

NervGen Pharma (NASDAQ:NGEN) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

NervGen Pharma presently has a consensus target price of $14.00, suggesting a potential upside of 503.45%. Werewolf Therapeutics has a consensus target price of $4.00, suggesting a potential upside of 323.82%. Given NervGen Pharma's stronger consensus rating and higher possible upside, research analysts clearly believe NervGen Pharma is more favorable than Werewolf Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NervGen Pharma
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
2 Strong Buy rating(s)
2.83
Werewolf Therapeutics
1 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.14

In the previous week, NervGen Pharma had 1 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 1 mentions for NervGen Pharma and 0 mentions for Werewolf Therapeutics. NervGen Pharma's average media sentiment score of 0.00 equaled Werewolf Therapeutics'average media sentiment score.

Company Overall Sentiment
NervGen Pharma Neutral
Werewolf Therapeutics Neutral

NervGen Pharma has higher earnings, but lower revenue than Werewolf Therapeutics. NervGen Pharma is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NervGen PharmaN/AN/A-$31.58M-$0.46N/A
Werewolf Therapeutics$1.88M24.40-$60.82M-$0.76N/A

Werewolf Therapeutics' return on equity of -166.99% beat NervGen Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
NervGen PharmaN/A -1,259.82% -199.79%
Werewolf Therapeutics N/A -166.99%-59.88%

64.8% of Werewolf Therapeutics shares are owned by institutional investors. 5.8% of NervGen Pharma shares are owned by company insiders. Comparatively, 23.6% of Werewolf Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

NervGen Pharma and Werewolf Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Werewolf Therapeutics compare to MediWound?

Werewolf Therapeutics (NASDAQ:HOWL) and MediWound (NASDAQ:MDWD) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.

In the previous week, MediWound had 6 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 6 mentions for MediWound and 0 mentions for Werewolf Therapeutics. MediWound's average media sentiment score of 0.37 beat Werewolf Therapeutics' score of 0.00 indicating that MediWound is being referred to more favorably in the news media.

Company Overall Sentiment
Werewolf Therapeutics Neutral
MediWound Neutral

MediWound has higher revenue and earnings than Werewolf Therapeutics. MediWound is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Werewolf Therapeutics$1.88M24.40-$60.82M-$0.76N/A
MediWound$16.96M10.01-$23.88M-$1.80N/A

Werewolf Therapeutics has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market. Comparatively, MediWound has a beta of 0.14, meaning that its share price is 86% less volatile than the broader market.

64.8% of Werewolf Therapeutics shares are owned by institutional investors. Comparatively, 46.8% of MediWound shares are owned by institutional investors. 23.6% of Werewolf Therapeutics shares are owned by insiders. Comparatively, 9.2% of MediWound shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Werewolf Therapeutics has a net margin of 0.00% compared to MediWound's net margin of -170.10%. MediWound's return on equity of -47.24% beat Werewolf Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Werewolf TherapeuticsN/A -166.99% -59.88%
MediWound -170.10%-47.24%-24.27%

Werewolf Therapeutics presently has a consensus target price of $4.00, suggesting a potential upside of 323.82%. MediWound has a consensus target price of $33.00, suggesting a potential upside of 149.81%. Given Werewolf Therapeutics' higher possible upside, analysts plainly believe Werewolf Therapeutics is more favorable than MediWound.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Werewolf Therapeutics
1 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.14
MediWound
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Summary

Werewolf Therapeutics beats MediWound on 8 of the 15 factors compared between the two stocks.

How does Werewolf Therapeutics compare to Tenaya Therapeutics?

Tenaya Therapeutics (NASDAQ:TNYA) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Tenaya Therapeutics' return on equity of -83.75% beat Werewolf Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Tenaya TherapeuticsN/A -83.75% -66.53%
Werewolf Therapeutics N/A -166.99%-59.88%

90.5% of Tenaya Therapeutics shares are held by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are held by institutional investors. 2.5% of Tenaya Therapeutics shares are held by insiders. Comparatively, 23.6% of Werewolf Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Tenaya Therapeutics presently has a consensus price target of $4.00, suggesting a potential upside of 475.29%. Werewolf Therapeutics has a consensus price target of $4.00, suggesting a potential upside of 323.82%. Given Tenaya Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Tenaya Therapeutics is more favorable than Werewolf Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tenaya Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86
Werewolf Therapeutics
1 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.14

In the previous week, Tenaya Therapeutics had 3 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 3 mentions for Tenaya Therapeutics and 0 mentions for Werewolf Therapeutics. Tenaya Therapeutics' average media sentiment score of 0.44 beat Werewolf Therapeutics' score of 0.00 indicating that Tenaya Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Tenaya Therapeutics Neutral
Werewolf Therapeutics Neutral

Tenaya Therapeutics has a beta of 2.77, meaning that its stock price is 177% more volatile than the broader market. Comparatively, Werewolf Therapeutics has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market.

Werewolf Therapeutics has higher revenue and earnings than Tenaya Therapeutics. Tenaya Therapeutics is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tenaya TherapeuticsN/AN/A-$90.60M-$0.53N/A
Werewolf Therapeutics$1.88M24.40-$60.82M-$0.76N/A

Summary

Tenaya Therapeutics beats Werewolf Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Werewolf Therapeutics compare to OnKure Therapeutics?

Werewolf Therapeutics (NASDAQ:HOWL) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.

OnKure Therapeutics' return on equity of -49.01% beat Werewolf Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Werewolf TherapeuticsN/A -166.99% -59.88%
OnKure Therapeutics N/A -49.01%-45.77%

64.8% of Werewolf Therapeutics shares are owned by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are owned by institutional investors. 23.6% of Werewolf Therapeutics shares are owned by insiders. Comparatively, 2.2% of OnKure Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Werewolf Therapeutics has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market. Comparatively, OnKure Therapeutics has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market.

In the previous week, OnKure Therapeutics had 3 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 3 mentions for OnKure Therapeutics and 0 mentions for Werewolf Therapeutics. Werewolf Therapeutics' average media sentiment score of 0.00 equaled OnKure Therapeutics'average media sentiment score.

Company Overall Sentiment
Werewolf Therapeutics Neutral
OnKure Therapeutics Neutral

OnKure Therapeutics has lower revenue, but higher earnings than Werewolf Therapeutics. Werewolf Therapeutics is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Werewolf Therapeutics$1.88M24.40-$60.82M-$0.76N/A
OnKure TherapeuticsN/AN/A-$59.52M-$3.50N/A

Werewolf Therapeutics currently has a consensus target price of $4.00, suggesting a potential upside of 323.82%. OnKure Therapeutics has a consensus target price of $17.50, suggesting a potential upside of 391.57%. Given OnKure Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe OnKure Therapeutics is more favorable than Werewolf Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Werewolf Therapeutics
1 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.14
OnKure Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Summary

OnKure Therapeutics beats Werewolf Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Werewolf Therapeutics compare to Connect Biopharma?

Werewolf Therapeutics (NASDAQ:HOWL) and Connect Biopharma (NASDAQ:CNTB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

Werewolf Therapeutics presently has a consensus price target of $4.00, suggesting a potential upside of 323.82%. Connect Biopharma has a consensus price target of $7.43, suggesting a potential upside of 284.90%. Given Werewolf Therapeutics' higher probable upside, equities analysts clearly believe Werewolf Therapeutics is more favorable than Connect Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Werewolf Therapeutics
1 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.14
Connect Biopharma
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.75

Werewolf Therapeutics has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market. Comparatively, Connect Biopharma has a beta of -0.23, meaning that its share price is 123% less volatile than the broader market.

Connect Biopharma has lower revenue, but higher earnings than Werewolf Therapeutics. Connect Biopharma is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Werewolf Therapeutics$1.88M24.40-$60.82M-$0.76N/A
Connect Biopharma$60K2,025.54-$55.48M-$1.19N/A

Connect Biopharma's return on equity of -165.41% beat Werewolf Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Werewolf TherapeuticsN/A -166.99% -59.88%
Connect Biopharma N/A -165.41%-121.58%

64.8% of Werewolf Therapeutics shares are owned by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are owned by institutional investors. 23.6% of Werewolf Therapeutics shares are owned by company insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Connect Biopharma had 3 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 3 mentions for Connect Biopharma and 0 mentions for Werewolf Therapeutics. Connect Biopharma's average media sentiment score of 0.13 beat Werewolf Therapeutics' score of 0.00 indicating that Connect Biopharma is being referred to more favorably in the news media.

Company Overall Sentiment
Werewolf Therapeutics Neutral
Connect Biopharma Neutral

Summary

Werewolf Therapeutics beats Connect Biopharma on 8 of the 15 factors compared between the two stocks.

Get Werewolf Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for HOWL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HOWL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HOWL vs. The Competition

Export
MetricWerewolf TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$48.52M$4.03B$7.26B$12.73B
Dividend YieldN/A3.60%2.53%8.86%
P/E Ratio-1.2412.66273.2925.38
Price / Sales24.401,309.08613.4592.55
Price / CashN/A106.8777.8252.26
Price / Book2.7816.2912.896.14
Net Income-$60.82M-$22.72M$3.47B$349.01M
7 Day Performance0.05%0.34%0.60%-0.27%
1 Month Performance127.64%8.52%5.73%0.68%
1 Year Performance-30.09%52.66%25.35%14.84%

Werewolf Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HOWL
Werewolf Therapeutics
2.625 of 5 stars		$0.94
-5.5%		$4.00
+323.8%		-31.1%$48.52M$1.88MN/A40
NGEN
NervGen Pharma
1.6012 of 5 stars		$2.09
+4.5%		$14.00
+569.9%		N/A$168.52MN/AN/AN/A
MDWD
MediWound
2.0579 of 5 stars		$12.96
-0.3%		$33.00
+154.6%		-20.3%$166.56M$11.86MN/A80
TNYA
Tenaya Therapeutics
2.1504 of 5 stars		$0.70
+4.3%		$4.00
+468.5%		-41.1%$157.77M$1.34MN/A110
OKUR
OnKure Therapeutics
2.8534 of 5 stars		$3.86
-0.8%		$17.50
+353.4%		+25.8%$155.94MN/AN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:HOWL) was last updated on 9/4/2026 by MarketBeat.com Staff.
From Our Partners
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
How Long Does $2.5M Last in Retirement?
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...
SmartAsset | Sponsoredtc pixel
Bezos… DOOMED
A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...
Paradigm Press | Sponsoredtc pixel
Before Anthropic becomes impossible to ignore...
Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
A new income category is drawing serious money - here's why
Forbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...
Investors Alley | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
In 1984, a 10000 dollar stake in Apple could have grown to 25 million dollars for early investors who simply g...
Eagle Publishing | Sponsoredtc pixel